The Liquid Biopsy Summit

Join your peers and colleagues in San Francisco to gain insight and perspective on why molecular liquid biopsies have the potential to become a fulcrum in the future of precision medicine.

This is an unprecedented time in biomolecular medicine. Recent scientific findings have determined biofluids consist of circulating cell-free (cf)DNA and extracellular (ex)RNA from multiple tissues within the body. In addition, the rapid development of highly sensitive and accurate next-generation sequencing (NGS) technologies has empowered researchers to analyze the role of these biomolecules in health, disease and treatment response. However, there remains considerable insecurity associated with biofluid-based DNA/RNA analytical methods which must be solved before liquid biopsies can be implemented for broader routine applications.